Marina Biotech makes organisational changes
Creates the position of executive vice president of r&d
Richard Ho has joined the firm in the newly created position of executive vice president, Research and Development.
In addition, Philip Ranker has become interim chief financial officer, replacing Peter Garcia who has resigned from the role to pursue other opportunities.
Barry Polisky has moved from chief scientific officer to distinguished scientist and has become chairman of the firm's Scientific Advisory Panel and Michael Templin has been promoted to the newly created position of senior vice president and chief technology officer.
Finally, Alan Dunton has joined the firm as consulting chief medical officer.
Marina Biotech’s goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies.
You may also like
Research & Development
€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment
The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes
Regulatory
FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment
The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Research & Development
Vivan Therapeutics and MRC LMS launch partnership to study how KRAS mutations, diabetes and diet shape cancer drug response
The new collaboration will investigate how KRAS mutations and metabolic conditions such as diabetes influence chemotherapy effectiveness, using high-throughput in vivo “fly avatar” models